1 Wolng A, Clozel JP, Rein J, et al.Functional and biochemical analysis of angiotensin II-forming pathways in the human heart [J].Circ Res, 1997;80:219-227
2 Schmitz D, Berk BC.Angiotensin II signal transduction stimulation of mutiple mitogen activated protein kinase pathway s[J]. Trends Endocrinol Metab, 1997;8:261-6
3 Harris RC, Becker BN, Cheng HF.Acute and chronic mechanisms for regulating proximal tubule angiotensin II receptor expression[J].J Am Soc Nephrol, 1997;8:306-13
4 Klahr S, Morrissey JJ.Comprative study of ACE inhibitors and angiotensin II receptor antagonist in interstitial scarring [J]. Kidney Int, 1997;52(suppl 63):111-4
5 Gomez-Garre D, Largo R, Tejera N, et al.Activation of NF-κB in tubular epithelial cells of rats with intense proteinuria:Role of Angiotensin II and Endothelin-1[J].Hypertension, 2001;37: 1171-8
6 Ruiz-Ortega M, Lorenzo O, RuperezM, et al.AngiotensinII activates nuclear transcription factor κB through AT1 and AT2 in vascular smooth muscle cells:molecular mechanisms[J].Circ Res, 2000;86:1266-72
7 Wu LL, Yang N, Roe CJ, et al.Macrophage and myofibroblast proliferation in remnant kidney:Role of angitensin II[J].Kidney Int, 1997;52(suppl 63):221-5
8 Nakajima M, Hutchinson HG, Fujinaga M, et al.The angiotensin II type 2(AT2) receptor antagonizes the growth effects of the AT1 receptor:Gain-of-function study using gene transfer [J].Proc Natl Acad Sci USA, 1995;92:10663-7
9 Noda M, Fukuda R, Matsuo T, et al.Effects of Candesartan cilexetil (TCV-116) and enalapril in 5/6 nephrectomized rats [J].Kidney Int, 1997;52(suppl 63):136-9
10 Nakamura T, Obata J, Kimura H, et al.Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis[J].Kidney Int, 1999; 55:877-89
11 Leenen FH, Yuan B.Prevention of hypertension by irbesartan in dahl Srats relates to central angiotensin II type I receptor blockade[J].Hypertension, 2001;37:981-4
12 Neutel JM.Clinical studies of Cs-866, the newest angiotensin II receptor antagonist[J].Am J Cardiol, 2001;87(8A):37c-43
13 黄洁, 李一石, 孙兴昌, 等.依贝沙坦与苯那普利治疗原发性高血压比较[J].中国临床药学杂志, 2001;10:205-7
14 Lacourciere Y, Belarger A, Godin C, et al.Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy[J].Kidney Int, 2000;58:762-9
15 Bauduceau B, Genes N, Chamontin B, et al.Ambulatory blood pressure and urinary albumin excretion in diabetic (non-insulindependent) hypertensive patients:relationship at baseline and after treatment by the angiotensin converting enzyme inhibitor trandelapril[J].Am J Hypertens, 1998;11:1065-73
16 Obata J, Nakamura T, Kuroyanagi R, et al.Candesartan prevents the progression of glomerulosclerosis in genetic hypertensive rats[J].Kidney Int, 1997;52(suppl 63):229-31
17 袁曙光, 刘瑞洪, 夏运成, 等.血管紧张素II 受体拮抗剂对5/ 6 肾切除鼠的肾脏保护作用[J].中华肾脏病学杂志, 2001;17:41-5
18 卢筱华, 冯烈, 许敏华.氯沙坦对糖尿病大鼠肾脏保护作用的探讨[J].中华肾脏病学杂志, 2000;16:182-5
19 Buter H, Navis G, Dullaart RP, et al.Time course of the antiproteinuric and renal naemodynamic responses to losartan in microalbuminuric IDDM[J].Nephrol Dial Transplant, 2001; 16:771-5
20 Woo KT, Lau.YK, Wong KS, et al.ACEI/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis[J].Kidney Int, 2000;58:2485-91
21 Shahinfar S, Simpson RL, Carides AD, et al.Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia [J].Kidney Int, 1999;56:1879-85
22 Schmidt A, Gruber U, Bohmig G, et al.The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA[J].Nephrol Dial Transplant, 2001;16:1034-7
23 曾群英, 麦炜颐, 何清, 等.两种AT1 拮抗剂治疗轻中度原发性高血压的临床研究[J].中国临床药理学杂志, 2001;17:182-5
24 El-Dahr SS, Dipp S, Yosipiv IV, et al.Bradykinin stimulates cfos expression AP-1-DNA binding activity and proliferation of rat glomerular mesangial cell[J].Kidney Int, 1996;50:1850-5
25 Andersen S, Tarnow L, Rossing P, et al.Renoprotective effects of angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy[J].Kidney Int, 2000;57:601-6
26 Russo D, Pisani A, Balletta MM, et al.Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy[J].Am J Kidney Dis, 1999; 33:851-6
27 Chan J, Critchley JAJH, Tomlison B, et al.Antihypertensive and antialbuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin-dependent diabetes mellitus[J].Am J Nephrolo, 1997; 17:72-80
28 Bakris GL, Siomos M, Richardson D, et al.ACE inhibition or angiotensin receptor blockade:impact on potassium in renal failure[J].Kidney Int, 2000;58:2084-92 |
